Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Recent Omicron COVID-19 Subtypes is Rare but Involves Severe Cardiovascular Features - Scorecard - MDSpire
Advertisement
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Recent Omicron COVID-19 Subtypes is Rare but Involves Severe Cardiovascular Features
Clinical Scorecard: Rare Occurrence of Multisystem Inflammatory Syndrome in Children (MIS-C) Linked to Recent Omicron Variants of COVID-19 with Notable Cardiovascular Complications
At a Glance
Category
Detail
Condition
Multisystem Inflammatory Syndrome in Children (MIS-C)
Key Mechanisms
Associated with SARS-CoV-2 infection, leading to systemic inflammation and cardiovascular complications.
Target Population
Children and adolescents under 18 years old.
Care Setting
Tertiary referral center.
Key Highlights
Cardiac involvement occurs in up to 80% of MIS-C patients.
Severe complications include left ventricular dysfunction and coronary artery dilation.
Cardiovascular manifestations have decreased with Omicron variants compared to Delta.
MIS-C hospitalization rates are declining, likely due to vaccination and variant evolution.
Recent emergence of the JN.1 subtype raises concerns about MIS-C presentation.
Guideline-Based Recommendations
Diagnosis
Follow CDC diagnostic criteria for MIS-C, including fever, laboratory evidence of inflammation, and involvement of at least two organ systems.
Management
Utilize anti-inflammatory therapies for cardiovascular involvement in MIS-C.
Monitoring & Follow-up
Monitor left ventricular systolic function and troponin levels during hospitalization.
Risks
Potential for severe coronary aneurysms and refractory left ventricular dysfunction.
Patient & Prescribing Data
Children diagnosed with MIS-C following COVID-19 infection.
Rapid resolution of cardiovascular findings is common with appropriate anti-inflammatory treatment.
Clinical Best Practices
Ensure multidisciplinary evaluation for MIS-C diagnosis.
Regular follow-up for cardiac function post-discharge.
Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.
